A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.
Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3-4 hours. Orally administered gabapentin exhibits saturable absorption--a nonlinear (zero-order) process--making its pharmacokinetics less predictable. Plasma concentrations of gabapentin do not increase proportionally with increasing dose. In contrast, orally administered pregabalin is absorbed more rapidly, with maximum plasma concentrations attained within 1 hour. Absorption is linear (first order), with plasma concentrations increasing proportionately with increasing dose. The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage. Both drugs can be given without regard to meals. Neither drug binds to plasma proteins. Neither drug is metabolized by nor inhibits hepatic enzymes that are responsible for the metabolism of other drugs. Both drugs are excreted renally, with elimination half-lives of approximately 6 hours. Pregabalin and gabapentin both show dose-response relationships in the treatment of postherpetic neuralgia and partial seizures. For neuropathic pain, a pregabalin dosage of 450 mg/day appears to reduce pain comparably to the predicted maximum effect of gabapentin. As an antiepileptic, pregabalin may be more effective than gabapentin, on the basis of the magnitude of the reduction in the seizure frequency. In conclusion, pregabalin appears to have some distinct pharmacokinetic advantages over gabapentin that may translate into an improved pharmacodynamic effect.
Bockbrader
Howard N
HN
Pfizer Global Research & Development, Ann Arbor, Michigan 48105, USA. howard.bockbrader@pfizer.com
Wesche
David
D
Miller
Raymond
R
Chapel
Sunny
S
Janiczek
Nancy
N
Burger
Paula
P
D000588:Amines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000700:Analgesics / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D000077206:Gabapentin; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
D000588:Amines; D000700:Analgesics; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
Trends Pharmacol Sci. 2007 Feb;28(2):75-82
17222465
J Clin Pharmacol. 2003 Mar;43(3):277-83
12638396
Neurology. 2003 May 27;60(10):1631-7
12771254
Neurology. 2005 Feb 8;64(3):475-80
15699378
Clin Pharmacol Ther. 1994 Aug;56(2):154-9
8062491
Epilepsy Res. 1998 Jan;29(2):161-6
9477149
J Biol Chem. 1996 Mar 8;271(10):5768-76
8621444
Neurology. 1993 Nov;43(11):2292-8
8232945
Mol Pharmacol. 2002 Apr;61(4):729-37
11901210
Pharm Res. 1993 Feb;10(2):276-81
8456077
Epilepsy Res. 1992 Mar;11(1):45-9
1373372
Drug Metab Dispos. 1995 Apr;23(4):441-8
7600909
Epilepsy Res. 2002 Dec;52(2):129-37
12458029
Curr Opin Pharmacol. 2006 Feb;6(1):108-13
16376147
Epilepsia. 2004 Jan;45(1):20-7
14692903
Seizure. 2003 Jan;12(1):28-36
12495646
Arzneimittelforschung. 1986 May;36(5):830-9
3730018
J Clin Pharmacol. 2010 Aug;50(8):941-50
20147618
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42
17088553
Epilepsia. 1994 Jul-Aug;35(4):795-801
8082624
Epilepsy Res. 2007 Feb;73(2):137-50
17126531
Pain. 2004 May;109(1-2):26-35
15082123
Neurology. 2003 Apr 22;60(8):1274-83
12707429
Br J Clin Pharmacol. 2006 Mar;61(3):246-55
16487217
JAMA. 1998 Dec 2;280(21):1837-42
9846778
Epilepsia. 2005 Oct;46(10):1621-4
16190933
Lancet. 1990 May 12;335(8698):1114-7
1971862
Curr Med Res Opin. 2006 Feb;22(2):375-84
16466610
Drugs. 2007;67(9):1265-89
17547471
Anesth Analg. 2000 Jul;91(1):185-91
10866910
J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15
15769862
Pharm Res. 2001 Aug;18(8):1126-30
11587483
Epilepsy Res. 2000 Jul;40(2-3):123-7
10863139
Pain. 2001 Nov;94(2):215-224
11690735
Eur J Pharmacol. 2000 Jun 9;398(1):53-7
10856447
Clin Pharmacokinet. 2007;46(3):209-19
17328580
Epilepsy Res. 1996 Feb;23(1):71-6
8925804
J Med Chem. 2005 Apr 7;48(7):2294-307
15801823
Eur J Pharmacol. 1993 Nov 15;247(3):341-5
8307106